Cargando…

The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time

PURPOSE: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are widely used for the treatment of advanced estrogen receptor (ER)-positive breast cancer. To develop a treatment strategy for cancers resistant to CDK4/6 inhibitors, here, we established palbociclib-resistant sublines and analyzed their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ono, Mayu, Oba, Takaaki, Shibata, Tomohiro, Ito, Ken-ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484193/ https://www.ncbi.nlm.nih.gov/pubmed/34244855 http://dx.doi.org/10.1007/s00432-021-03722-3

Ejemplares similares

Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer
por: Watanabe, Takayuki, et al.
Publicado: (2021)

Lipid-rich carcinoma of the breast that is strongly positive for estrogen receptor: a case report and literature review
por: Oba, Takaaki, et al.
Publicado: (2016)

Palbociclib enhances activin‐SMAD‐induced cytostasis in estrogen receptor‐positive breast cancer
por: Harada, Mayumi, et al.
Publicado: (2018)

Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer
por: Oba, Takaaki, et al.
Publicado: (2020)

Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy
por: Lypova, Nadiia, et al.
Publicado: (2019)

Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers
por: Raj, Ganesh V, et al.
Publicado: (2017)

Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancer
por: Tsukamoto, Fumine, et al.
Publicado: (2021)

Individual transcriptional activity of estrogen receptors in primary breast cancer and its clinical significance
por: Gohno, Tatsuyuki, et al.
Publicado: (2012)

Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3
por: Iwata, Hiroji, et al.
Publicado: (2021)

Differential impact of the expression of the androgen receptor by age in estrogen receptor–positive breast cancer
por: Tokunaga, Eriko, et al.
Publicado: (2013)

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
por: Di Cosimo, Serena, et al.
Publicado: (2022)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination
por: Chowdhary, Mudit, et al.
Publicado: (2019)

Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition
por: Oba, Takaaki, et al.
Publicado: (2018)

Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up
por: Finn, Richard S., et al.
Publicado: (2021)

Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer
por: Boér, Katalin
Publicado: (2016)

Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
por: Cheng, Yu-Chen, et al.
Publicado: (2023)

Targeting mutant estrogen receptors
por: Wardell, Suzanne E, et al.
Publicado: (2019)

Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor‐Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care‐BC): A Randomized Controlled Phase III Trial
por: Niikura, Naoki, et al.
Publicado: (2019)

Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor‐Positive Metastatic Breast Cancer
por: Jin, Liang, et al.
Publicado: (2020)

Papillary thyroid microcarcinoma with lung metastases: a case report and review of the literature
por: Shimizu, Tadafumi, et al.
Publicado: (2021)

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
por: Sun, James, et al.
Publicado: (2021)

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
por: Saleh, Lubaid, et al.
Publicado: (2023)

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial
por: Diéras, Véronique, et al.
Publicado: (2019)

Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer
por: Xia, Song, et al.
Publicado: (2022)

Fibroadenoma in a young male breast: A case report and review of the literature
por: Morikawa, Hiroki, et al.
Publicado: (2021)

Development of a predictive score for post-hemithyroidectomy hypothyroidism using skeletal muscle index, remnant thyroid index, and thyroid-stimulating hormone levels: a retrospective cohort study
por: Amitani, Masatsugu, et al.
Publicado: (2023)

Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice
por: Rath, Sushmita, et al.
Publicado: (2021)

ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines
por: Oba, Takaaki, et al.
Publicado: (2016)

The Advantage of Using an Optical See-Through Head-Mounted Display in Ultrasonography-Guided Needle Biopsy Procedures: A Prospective Randomized Study
por: Shimizu, Tadafumi, et al.
Publicado: (2023)

Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer
por: Grinshpun, Albert
Publicado: (2023)

Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine
por: Levin, Maren K, et al.
Publicado: (2015)

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer
por: Dowsett, Mitch, et al.
Publicado: (2022)

Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
por: Amitani, Masatsugu, et al.
Publicado: (2022)

Heat shock factor 1 (HSF1) cooperates with estrogen receptor α (ERα) in the regulation of estrogen action in breast cancer cells
por: Vydra, Natalia, et al.
Publicado: (2021)

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
por: Takahashi, Masato, et al.
Publicado: (2020)

Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells
por: Ohno, Koichi, et al.
Publicado: (2022)

FGF2-FGFR1 pathway activation together with thymidylate synthase upregulation is induced in pemetrexed-resistant lung cancer cells
por: Miura, Kentaro, et al.
Publicado: (2019)

Breast metastases of gastric signet-ring cell carcinoma: a report of two cases and review of the literature
por: Iesato, Asumi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i2qunnnslianlin19d3ftfsnd3